Supervised resistance exercise for women with ovarian cancer who have completed first-line treatment: a pragmatic study

被引:8
作者
Schofield, Christelle [1 ,5 ]
Newton, Robert U. [1 ,5 ]
Taaffe, Dennis R. [1 ,5 ]
Galvao, Daniel A. [1 ,5 ]
Cohen, Paul A. [2 ,3 ,5 ]
Meniawy, Tarek M. [2 ,3 ,4 ,5 ]
Peddle-McIntyre, Carolyn J. [1 ,5 ]
机构
[1] Edith Cowan Univ, Exercise Med Res Inst, Joondalup, WA, Australia
[2] Univ Western Australia, Sch Med, Crawley, WA, Australia
[3] St John God Hosp, Subiaco, WA, Australia
[4] Sir Charles Gairdner Hosp, Nedlands, WA, Australia
[5] Edith Cowan Univ, Sch Med & Hlth Sci, Joondalup, WA, Australia
关键词
Ovarian cancer; Resistance exercise; Muscle mass; Muscle strength; Physical function; FEMALE PELVIC FLOOR; QUALITY-OF-LIFE; OLDER-ADULTS; ACTIVITY BEHAVIORS; PHYSICAL-ACTIVITY; CONTROLLED-TRIAL; CHEMOTHERAPY; SURVIVORS; MYOSTEATOSIS; SARCOPENIA;
D O I
10.1007/s00520-023-07754-y
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
ObjectivesIn ovarian cancer (OC), suboptimal muscle morphology (i.e., low muscle mass and density) is associated with poor clinical outcomes, yet little is known about the effect of interventions aimed at improving these measures. We investigated the effect of resistance exercise after first-line treatment on muscle mass and density, muscle strength and physical function, health-related quality of life (QoL), and pelvic-floor function in advanced-stage OC survivors.MethodsFifteen OC survivors participated in supervised resistance exercise twice weekly for 12 weeks (in-clinic or by telehealth). Assessments included muscle mass and density (dual-energy X-ray absorptiometry, peripheral quantitative computed tomography), muscle strength (1-repetition maximum [1RM] chest press, 5RM leg press, handgrip strength), physical function (400-m walk, timed up-and-go [TUG]), QoL (QLQ-C30 questionnaire), and self-reported pelvic floor function (Australian Pelvic Floor Questionnaire).ResultsThe median age was 64 (range 33-72) years, 10 women underwent neoadjuvant chemotherapy and five underwent adjuvant chemotherapy. All participants completed the intervention (median attendance = 92%; range 79-100%). Post-intervention improvements were observed for whole-body lean mass (1.0 +/- 1.4 kg, p = 0.015), appendicular lean mass (0.6 +/- 0.9 kg, p = 0.013), muscle density (p = 0.011), upper and lower body strength (p <= 0.001), 400-m walk (p = 0.001), TUG (p = 0.005), and social and cognitive QoL domains (p = 0.002 and 0.007), with no change to pelvic floor symptoms (p > 0.05).ConclusionIn this study, supervised resistance exercise effectively improved muscle mass and density, muscle strength, and physical functioning without deleterious effects on the pelvic floor. Considering the prognostic value of these outcomes, larger studies are needed to confirm the benefits of resistance exercise in OC supportive care.
引用
收藏
页数:12
相关论文
共 50 条
[31]   Brain structure and function in patients with ovarian cancer treated with first-line chemotherapy: a pilot study [J].
D. D. Correa ;
J. C. Root ;
M. Kryza-Lacombe ;
M. Mehta ;
S. Karimi ;
M. L. Hensley ;
N. Relkin .
Brain Imaging and Behavior, 2017, 11 :1652-1663
[32]   Usefulness of osteopontin (OPN) determinations in ovarian cancer patients who underwent first-line chemotherapy [J].
Mrochem-Kwarciak, Jolanta ;
Mrochen-Domin, Izolda ;
Wojcieszek, Andrzej ;
Deja, Regina ;
Chmura, Aleksandra ;
Maslyk, Barbara ;
Nowara, Elzbieta ;
Kaleta, Beata ;
Kolosza, Zofia ;
Bartnik, Wieslawa .
GINEKOLOGIA POLSKA, 2011, 82 (12) :911-917
[33]   Neo-Adjuvant Chemotherapy Reduces, and Surgery Increases Immunosuppression in First-Line Treatment for Ovarian Cancer [J].
De Bruyn, Christine ;
Ceusters, Jolien ;
Landolfo, Chiara ;
Baert, Thais ;
Thirion, Gitte ;
Claes, Sandra ;
Vankerckhoven, Ann ;
Wouters, Roxanne ;
Schols, Dominique ;
Timmerman, Dirk ;
Vergote, Ignace ;
Coosemans, An .
CANCERS, 2021, 13 (23)
[34]   Individualization in the first-line treatment of advanced ovarian cancer based on the mechanism of action of molecularly targeted drugs [J].
Nakai, Hidekatsu ;
Matsumura, Noriomi .
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2022, 27 (06) :1001-1012
[35]   Selection of maintenance therapy during first-line treatment of advanced ovarian cancer based on pharmacologic characteristics [J].
Nakai, Hidekatsu ;
Matsumura, Noriomi .
EXPERT OPINION ON PHARMACOTHERAPY, 2023, 24 (18) :2161-2173
[36]   Ovarian Cancer Treatment Drug Everolimus Inhibits the Metabolic Elimination of First-Line Anti-Colon Cancer Irinotecan [J].
Wang, Hui ;
Li, Hui ;
Zhang, Qian ;
Zhao, Dongmei ;
Xiao, Yu-Feng .
LATIN AMERICAN JOURNAL OF PHARMACY, 2017, 36 (06) :1250-1254
[37]   A phase II study of weekly carboplatin and paclitaxel as first-line treatment of elderly patients with advanced ovarian cancer - A Multicentre Italian Trial in Ovarian cancer (MITO-5) study [J].
Pignata, Sandro ;
Breda, Enrico ;
Scambia, Giovanni ;
Pisano, Carmela ;
Zagonel, Vittorina ;
Lorusso, Domenica ;
Greggi, Stefano ;
De Vivo, Rocco ;
Ferrandina, Gabriella ;
Gallo, Ciro ;
Perrone, Francesco .
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2008, 66 (03) :229-236
[38]   A multicenter phase II study of cisplatin and docetaxel (Taxotere) in the first-line treatment of advanced ovarian cancer: a GINECO study [J].
Véronique Diéras ;
Jean Paul Guastalla ;
Jean Marc Ferrero ;
Hervé Curé ;
Béatrice Weber ;
Philippe Winckel ;
Alain Lortholary ;
Françoise Mayer ;
Désiré Paraiso ;
Emmanuelle Magherini ;
Eric Pujade-Lauraine .
Cancer Chemotherapy and Pharmacology, 2004, 53 :489-495
[39]   A multicenter phase II study of cisplatin and docetaxel (Taxotere) in the first-line treatment of advanced ovarian cancer:: a GINECO study [J].
Diéras, V ;
Guastalla, JP ;
Ferrero, JM ;
Curé, H ;
Weber, B ;
Winckel, P ;
Lortholary, A ;
Mayer, F ;
Paraiso, D ;
Magherini, E ;
Pujade-Lauraine, E .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2004, 53 (06) :489-495
[40]   Treatment preferences of advanced ovarian cancer patients for adding bevacizumab to first-line therapy [J].
Lee, Jung-Yun ;
Kim, Kyunghoon ;
Lee, Yun Shin ;
Kim, Hyo Young ;
Nam, Eun Ji ;
Kim, Sunghoon ;
Kim, Sang Wun ;
Kim, Jae Weon ;
Kim, Young Tae .
GYNECOLOGIC ONCOLOGY, 2016, 143 (03) :622-627